QQQ   310.73 (-0.32%)
AAPL   156.73 (+3.92%)
MSFT   262.51 (-0.79%)
META   190.31 (+0.82%)
GOOGL   106.69 (-0.97%)
AMZN   106.96 (-5.27%)
TSLA   197.09 (+4.68%)
NVDA   215.78 (-0.60%)
NIO   11.69 (-2.26%)
BABA   107.23 (-2.29%)
AMD   88.02 (-0.33%)
T   19.89 (-1.92%)
MU   63.53 (+0.57%)
F   13.30 (-7.12%)
CGC   3.07 (-2.23%)
GE   83.05 (-1.06%)
DIS   112.75 (-0.41%)
AMC   6.66 (+9.54%)
PFE   44.01 (-0.74%)
PYPL   86.83 (-0.15%)
NFLX   369.27 (+0.65%)
QQQ   310.73 (-0.32%)
AAPL   156.73 (+3.92%)
MSFT   262.51 (-0.79%)
META   190.31 (+0.82%)
GOOGL   106.69 (-0.97%)
AMZN   106.96 (-5.27%)
TSLA   197.09 (+4.68%)
NVDA   215.78 (-0.60%)
NIO   11.69 (-2.26%)
BABA   107.23 (-2.29%)
AMD   88.02 (-0.33%)
T   19.89 (-1.92%)
MU   63.53 (+0.57%)
F   13.30 (-7.12%)
CGC   3.07 (-2.23%)
GE   83.05 (-1.06%)
DIS   112.75 (-0.41%)
AMC   6.66 (+9.54%)
PFE   44.01 (-0.74%)
PYPL   86.83 (-0.15%)
NFLX   369.27 (+0.65%)
QQQ   310.73 (-0.32%)
AAPL   156.73 (+3.92%)
MSFT   262.51 (-0.79%)
META   190.31 (+0.82%)
GOOGL   106.69 (-0.97%)
AMZN   106.96 (-5.27%)
TSLA   197.09 (+4.68%)
NVDA   215.78 (-0.60%)
NIO   11.69 (-2.26%)
BABA   107.23 (-2.29%)
AMD   88.02 (-0.33%)
T   19.89 (-1.92%)
MU   63.53 (+0.57%)
F   13.30 (-7.12%)
CGC   3.07 (-2.23%)
GE   83.05 (-1.06%)
DIS   112.75 (-0.41%)
AMC   6.66 (+9.54%)
PFE   44.01 (-0.74%)
PYPL   86.83 (-0.15%)
NFLX   369.27 (+0.65%)
QQQ   310.73 (-0.32%)
AAPL   156.73 (+3.92%)
MSFT   262.51 (-0.79%)
META   190.31 (+0.82%)
GOOGL   106.69 (-0.97%)
AMZN   106.96 (-5.27%)
TSLA   197.09 (+4.68%)
NVDA   215.78 (-0.60%)
NIO   11.69 (-2.26%)
BABA   107.23 (-2.29%)
AMD   88.02 (-0.33%)
T   19.89 (-1.92%)
MU   63.53 (+0.57%)
F   13.30 (-7.12%)
CGC   3.07 (-2.23%)
GE   83.05 (-1.06%)
DIS   112.75 (-0.41%)
AMC   6.66 (+9.54%)
PFE   44.01 (-0.74%)
PYPL   86.83 (-0.15%)
NFLX   369.27 (+0.65%)
NASDAQ:OCX

OncoCyte - OCX Stock Forecast, Price & News

$0.38
-0.01 (-3.30%)
(As of 02/3/2023 10:46 AM ET)
Add
Compare
Today's Range
$0.37
$0.39
50-Day Range
$0.25
$0.50
52-Week Range
$0.24
$1.75
Volume
87,872 shs
Average Volume
196,147 shs
Market Capitalization
$44.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.35

OncoCyte MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
247.5% Upside
$1.35 Price Target
Short Interest
Healthy
1.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$7,000 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.38) to ($0.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

260th out of 1,029 stocks

Diagnostic Substances Industry

4th out of 15 stocks

OCX stock logo

About OncoCyte (NASDAQ:OCX) Stock

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Stock News Headlines

OncoCyte Co. (NASDAQ:OCX) Sees Significant Drop in Short Interest
Elon Musk Claims Solar Will Soon Power the World
The world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
Oncocyte Announces Initiatives to Focus Corporate Strategy
Oncocyte Announces Executive Leadership Changes
Biotech Stock Alert
Read Small Pharma's depression clinical trial results.
OncoCyte (OCX) Reports Q3 Loss, Misses Revenue Estimates
Oncocyte Reports Third Quarter 2022 Financial Results
Oncocyte to Announce Third Quarter 2022 Financial Results
OncoCyte Corporation (OCX)
See More Headlines
Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Company Calendar

Last Earnings
11/10/2022
Today
2/03/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCX
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.35
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$0.50
Forecasted Upside/Downside
+259.8%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-64,100,000.00
Net Margins
-787.97%
Pretax Margin
-786.76%

Debt

Sales & Book Value

Annual Sales
$7.73 million
Book Value
$0.71 per share

Miscellaneous

Free Float
113,827,000
Market Cap
$44.51 million
Optionable
Optionable
Beta
1.73

Key Executives

  • Joshua Riggs
    Chief Executive Officer
  • Anish John
    Chief Financial Officer & Senior Vice President
  • Ekkehard Schütz
    Chief Technology Officer
  • Mitchell Stuart Levine
    Corporate Development Officer
  • Padma Sundar
    Chief Commercial Officer













OCX Stock - Frequently Asked Questions

Should I buy or sell OncoCyte stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OCX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OCX, but not buy additional shares or sell existing shares.
View OCX analyst ratings
or view top-rated stocks.

What is OncoCyte's stock price forecast for 2023?

4 brokers have issued 12-month price objectives for OncoCyte's stock. Their OCX share price forecasts range from $0.50 to $3.00. On average, they expect the company's share price to reach $1.35 in the next year. This suggests a possible upside of 255.3% from the stock's current price.
View analysts price targets for OCX
or view top-rated stocks among Wall Street analysts.

How have OCX shares performed in 2023?

OncoCyte's stock was trading at $0.3209 at the start of the year. Since then, OCX shares have increased by 18.4% and is now trading at $0.38.
View the best growth stocks for 2023 here
.

Are investors shorting OncoCyte?

OncoCyte saw a decline in short interest in January. As of January 15th, there was short interest totaling 1,410,000 shares, a decline of 16.6% from the December 31st total of 1,690,000 shares. Based on an average trading volume of 414,300 shares, the short-interest ratio is presently 3.4 days.
View OncoCyte's Short Interest
.

When is OncoCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our OCX earnings forecast
.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NASDAQ:OCX) issued its earnings results on Thursday, November, 10th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The business had revenue of $1.02 million for the quarter, compared to the consensus estimate of $1.50 million. OncoCyte had a negative net margin of 787.97% and a negative trailing twelve-month return on equity of 54.99%.

What other stocks do shareholders of OncoCyte own?
What is OncoCyte's stock symbol?

OncoCyte trades on the NASDAQ under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Defender Capital LLC. (1.92%), Penbrook Management LLC (0.18%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Albert P Parker, Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Mitchell S Levine, Pura Vida Investments, Llc and Ronald Asbury Andrews.
View institutional ownership trends
.

How do I buy shares of OncoCyte?

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $0.38.

How much money does OncoCyte make?

OncoCyte (NASDAQ:OCX) has a market capitalization of $45.08 million and generates $7.73 million in revenue each year. The company earns $-64,100,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How can I contact OncoCyte?

OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at (949) 409-7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389.

This page (NASDAQ:OCX) was last updated on 2/3/2023 by MarketBeat.com Staff